Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 9Cetuximab 9Radiotherapy, Intensity-Modulated 7Everolimus 4Docetaxel 3Carboplatin 3Biopsy 3130-nm albumin-bound paclitaxel 3Ultrasonography 2Taxes 2Radiotherapy 2Radiation 2Photochemotherapy 2Paclitaxel 2Microarray Analysis 2Immunohistochemistry 2Gene Expression Profiling 2Fluorouracil 2Erlotinib Hydrochloride 2Cryosurgery 2Albumin-Bound Paclitaxel 21-phenyl-3,3-dimethyltriazene 2temoporfin 1talactoferrin alfa 1sargramostim 1pimonidazole 1pembrolizumab 1Zinc Oxide 1X-Rays 1Vaccinium myrtillus extract 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Tongue Neoplasms × talactoferrin alfa × Clear all
NCT01528137 2016-08-02

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

Stanford University

Phase 1 Terminated
4 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡